Andrew B Nixon

Andrew B Nixon

Duke University

H-index: 37

North America-United States

About Andrew B Nixon

Andrew B Nixon, With an exceptional h-index of 37 and a recent h-index of 28 (since 2020), a distinguished researcher at Duke University, specializes in the field of Oncology, Biomarker Development.

His recent articles reflect a diverse array of research interests and contributions to the field:

CCALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C infection in Patients with advanced hepatocellular carcinoma

Glycosaminoglycan modifications of betaglycan regulate ectodomain shedding to fine-tune TGF-β signaling responses in ovarian cancer

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or …

Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapies

Heparan sulfate modifications of betaglycan promote TIMP3-dependent ectodomain shedding to fine-tune TGF-β signaling.

Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial

Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.

Andrew B Nixon Information

University

Position

Professor of Medicine

Citations(all)

7068

Citations(since 2020)

3223

Cited By

5125

hIndex(all)

37

hIndex(since 2020)

28

i10Index(all)

92

i10Index(since 2020)

66

Email

University Profile Page

Duke University

Google Scholar

View Google Scholar Profile

Andrew B Nixon Skills & Research Interests

Oncology

Biomarker Development

Top articles of Andrew B Nixon

Title

Journal

Author(s)

Publication Date

CCALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C infection in Patients with advanced hepatocellular carcinoma

Cancer Research Communications

Ghassan K Abou-Alfa

Susan M Geyer

Andrew B Nixon

Federico Innocenti

Qian Shi

...

2024/2/16

Glycosaminoglycan modifications of betaglycan regulate ectodomain shedding to fine-tune TGF-β signaling responses in ovarian cancer

Cell Communication and Signaling

Alex S Choi

Laura M Jenkins-Lane

Wade Barton

Asha Kumari

Carly Lancaster

...

2024/2/15

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or …

Prostate Cancer and Prostatic Diseases

Andrew B Nixon

Yingmiao Liu

Qian Yang

Bin Luo

Mark D Starr

...

2024/2/12

Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapies

Akram Yazdani

Azam Yazdani

Raul Mendez-Giraldez

Gianluigi Pillonetto

Esmat Samiei

...

2024/3/11

Heparan sulfate modifications of betaglycan promote TIMP3-dependent ectodomain shedding to fine-tune TGF-β signaling.

bioRxiv

Alex Seok Choi

Laura M Jenkins-Lane

Wade Barton

Asha Kumari

Carly Lancaster

...

2023

Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.

Helen Mackay

Andrew B Nixon

Danielle Enserro

David Bender

BJ Rimel

...

2023/6/1

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial

Communications Medicine

Manmeet S Ahluwalia

Lisa R Rogers

Rekha Chaudhary

Herbert Newton

Ahmad Ozair

...

2023/9/8

Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.

Jaydira Del Rivero

Kimberly Perez

Susan Michelle Geyer

Maged F Khalil

Aishwarya Vijendran

...

2023/6/1

Circulating angiokines are associated with reverse remodeling and outcomes in chronic heart failure

Journal of Cardiac Failure

JOSEPHINE Harrington

Andrew B Nixon

Melissa A Daubert

Eric Yow

James Januzzi

...

2023/6/1

High yield of pleural cell-free DNA for diagnosis of oncogenic mutations in lung adenocarcinoma

Chest

Kamran Mahmood

Parvathi Jampani

Jeffrey M Clarke

Steven Wolf

Xiaofei Wang

...

2023/7/1

4MO Homologous recombination (HR) status of platinum-responsive advanced triple-negative breast cancers (aTNBC) treated with olaparib as maintenance therapy

ESMO Open

TJY Tan

S Sammons

JL Fink

WS Ong

B Jaradi

...

2023/5/1

Spatial genomics to reveal an immunosuppressive tumor microenvironment after chemoradiation in head and neck cancer patients.

Jennifer Hsing Choe

Omar Jabado

Xiaoyin Sara Jiang

Li Fan

Patrick Franken

...

2023/6/1

Association of inflammatory biomarkers with survival among patients with stage III colon cancer

JAMA oncology

En Cheng

Qian Shi

Anthony F Shields

Andrew B Nixon

Ardaman P Shergill

...

2023/3/1

A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance …

Rona Yaeger

Qian Shi

Amylou C Dueck

Elie G Dib

Syed Mohammad Ali Kazmi

...

2023/6/1

Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy

Akram Yazdani

Heinz-Josef Lenz

Gianluigi Pillonetto

Raul Mendez-Giraldez

Azam Yazdani

...

2023/12/15

Ultra-sensitive, tumor-informed ctDNA profiling in patients with gastroesophageal cancer and treated with pembrolizumab and longitudinal ctDNA kinetics.

Andrew B Nixon

Lee McDaniel

Jingquan Jia

Charles Abbott

Lauren Howard

...

2023/6/1

A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations.

Kristen Keon Ciombor

Tyler J Zemla

Joleen M Hubbard

Jingquan Jia

Olumide B Gbolahan

...

2023/2/1

Correlation of single-cell cytokine secretion with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with capecitabine (C), bevacizumab (B …

Niharika B Mettu

Blake Waechter

Tyler J Zemla

Yingmiao Liu

John C Brady

...

2023/6/1

Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance)

medRxiv

Julia CF Quintanilha

Alexander B Sibley

Yingmiao Liu

Donna Niedzwiecki

Susan Halabi

...

2023/12/4

AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.

Evelyn Cantillo

Tyler J Zemla

John William Moroney

Edwin A Alvarez

Lauren Yauch

...

2023/6/1

See List of Professors in Andrew B Nixon University(Duke University)